FLAURA trial: overall survival results confirms the efficacy of osimertinib in the treatment of NSCLC

Final overall survival (OS) data from FLAURA trial presented at ESMO Congress 2019 confirm that osimertinib is an option for first-line treatment of patients with EGFR-mutated NSCLC, as reported by Prof. Martin Reck from Prof. Martin Reck, Krankenhaus Grosshansdorf, Grosshansdorf, Germany.


ESMO Congress 2019 abstract:

LBA5_PR – Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis